A cyclic peptide inhibitor of the SARS-CoV-2 main protease
Open Access
- 1 October 2021
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 221, 113530
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Aeronautics and Space Administration (19-EXO19-0070)
This publication has 61 references indexed in Scilit:
- Helical poly(arginine) mimics with superior cell-penetrating and molecular transporting propertiesChemical Science, 2013
- In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding InhibitorsJournal of the American Chemical Society, 2012
- Backbone rigidity and static presentation of guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptidesNature Communications, 2011
- CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fieldsJournal of Computational Chemistry, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Functionalized Analogues of an Unnatural Amino Acid that Mimics a Tripeptide β-StrandOrganic Letters, 2008
- Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug DesignJournal of Virology, 2008
- Scalable molecular dynamics with NAMDJournal of Computational Chemistry, 2005
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Comparison of simple potential functions for simulating liquid waterThe Journal of Chemical Physics, 1983